SBRT for bridging and downstaging HCC before transplant.

ABSTRACT:

Background & aims

Stereotactic body radiotherapy (SBRT) has emerged as a bridging/downstaging therapy for patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). This study evaluates the safety and outcomes of the use of SBRT in such patients.

Methods

A retrospective review was conducted from 2004 to 2019 on 88 adult patients with HCC receiving SBRT as bridging/downstaging therapy. Endpoints, included treatment-related toxicities, liver function decline, and LT probability post SBRT, were analyzed using competing risk analysis.

Results

SBRT was used for bridging in 58 (66%) patients and downstaging in 30 (34%). Most patients had compensated liver function pre-SBRT and were treated with a median SBRT dose of 36 Gy in six fractions. Toxicities

SUBMITTER: Li Z 

PROVIDER: S-EPMC12270628 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature